Jyong Biotech (NASDAQ:MENS) Stock Price Down 19.3% – Here’s What Happened

Jyong Biotech Ltd. (NASDAQ:MENS)’s stock price was down 19.3% during mid-day trading on Tuesday . The stock traded as low as $18.01 and last traded at $18.07. Approximately 151,391 shares changed hands during mid-day trading, a decline of 44% from the average daily volume of 269,087 shares. The stock had previously closed at $22.39.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Jyong Biotech in a report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

Jyong Biotech Price Performance

The firm’s 50-day simple moving average is $40.78.

Hedge Funds Weigh In On Jyong Biotech

An institutional investor recently bought a new position in Jyong Biotech stock. BNP Paribas Financial Markets purchased a new stake in shares of Jyong Biotech Ltd. (NASDAQ:MENS) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 1,698 shares of the company’s stock, valued at approximately $67,000.

Jyong Biotech Company Profile

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.